Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 + T-cell Counts

Authors:

Abstract
Introduction: It is unknown whether the increased risk of toxicities in antiretroviral-naive HIV-infected patients initiating nevirapine-based (NVPc) combination antiretroviral therapy (cART) with high CD4 + T-cell counts is also observed when NVPc is initiated in cART-experienced patients. Patients and methods: 1,571 EuroSIDA patients started NVPc after 1/1/1999, with CD4 + T-cell counts and viral load measured in the 6 months before starting treatment, and were stratified into four groups based on CD4 + T-cell counts at initiation of NVPc (high [H], >400/mm 3 or >250/mm 3 for male or female, respectively, or low [L], ≤400/mm 3 or ≤250/mm 3 for male or female) and prior antiretroviral experience (antiretroviral-naive [N] or -experienced [E]). Cox proportional hazards models compared the risks of discontinuation of nevirapine due to toxicities or patient/physician choice (TOXPC). Results: After adjustment, there was a significantly lower risk of discontinuation of nevirapine due to TOXPC in the HE group ( n=588; proportion discontinued by 3/12 months: 10/17%, respectively) than in HN (n=62; 21/32% respectively; overall relative hazard [RH]: 0.56; 95% confidence interval [CI]: 0.34–0.94; P=0.027). This difference was most pronounced during the first 3 months of NVPc (RH: 0.44; 95% CI: 0.23–0.87; P=0.017). There were no deaths in the 6 months after starting NVPc resulting from exposure to + T-cell counts.

This publication has 13 references indexed in Scilit: